EGFR/SRC-mediated EMT

Overview

epidermal growth factor receptor (EGFR)/SRC-mediated epithelial-mesenchymal transition (EMT) names the oncogenic axis in which the epidermal growth factor receptor and the non-receptor tyrosine kinase SRC act together to convert epithelial tumor cells into a mesenchymal, invasive state. EMT is a developmental program that tumors reactivate: cells dismantle their junctions, lose apical-basal polarity, switch cadherin expression, and acquire the motility, matrix-degrading capacity and apoptosis resistance that permit invasion and metastasis — as well as resistance to therapies that depend on epithelial proliferation.

The two kinases reinforce each other rather than acting in series. Ligand-activated EGFR recruits and activates SRC, and SRC in turn phosphorylates EGFR at sites that sustain signaling and alter its trafficking, so the pair forms a self-amplifying hub feeding PI3K/Akt1, RAS/MAPK and JAK2/STAT3 signaling pathway cascades. Their joint output stabilizes the EMT transcription factors SNAIL, SLUG, ZEB and TWIST, which repress E-cadherin, while SRC additionally phosphorylates β-catenin and the junctional proteins that hold cells together — a direct route from kinase activity to loss of adhesion. Induction of Matrix Metalloproteinase-9 (MMP-9) and related proteases completes the phenotype by degrading basement membrane. This mutual dependence is also why SRC activation is a common route of resistance to EGFR inhibitors, and why the two are targeted together.

The axis operates across oral, colorectal, liver cancer, breast, head and neck, bladder cancer, ovarian cancer and prostate tumors, and in lung and gastric Cancers, and network analyses consistently rank both kinases among the highest-degree hubs in cancer protein interaction networks. It is potentiated by cancer-associated fibroblast-derived signals including growth factors TGF-β1 and VEGF and FGF2-PI3K-Akt1 signaling, by microenvironmental cues such as hypoxia and nuclear factor kappa B activation, and by tumor-cell-intrinsic alterations including MYC proto-oncogene (MYC) amplification. Targeting EGFR and SRC individually or together is pursued to suppress proliferation, metastasis and treatment resistance at once, though EMT's reversibility — cells revert at metastatic sites — complicates the reading of any single-timepoint measurement.

Recent Publications Summary

Recent publications linked EGFR/SRC-mediated EMT to both mechanistic and therapeutic studies across several cancer and disease models. In oral cancer cells, imipramine was reported to target apoptosis, metastasis, and EGFR/SRC-mediated EMT, indicating that this process was examined as part of the drug’s anti-progression effects 42049326Apr. In glioma research, scutellarein inhibited proliferation, migration, and invasion, and network pharmacology/transcriptomic analyses suggested SRC as a potential target, consistent with broader modulation of signaling programs that can intersect with EMT-related behavior 41966746Apr. Similarly, natural-product and systems-pharmacology studies identified EGFR and SRC among predicted hub targets in cancer-related networks, including pancreatic cancer-related phenolic constituents from dusty miller extract and metabolites of sanguinarine 41895184Mar41844053Mar.

Other studies provided additional context for EGFR- and SRC-associated signaling in processes relevant to EMT. In hepatocellular carcinoma, bile acid efflux restoration via BSEP reduced EGFR signaling and reversed tyrosine kinase inhibitor resistance, underscoring the importance of EGFR-driven adaptive programs in tumor progression 41903671Mar. In prostate cancer, dual DNMT and EZH2 inhibition reactivated ADAMTS1, degraded collagen-rich stroma, suppressed FAK/MAPK mechanotransduction, and reversed epithelial-mesenchymal transition, highlighting an EMT-relevant axis that converges on extracellular matrix remodeling and signaling plasticity 42313934Jun. In ischemic stroke and diabetic kidney disease studies, SRC and EGFR were also identified among network-predicted targets, reflecting the broader involvement of these nodes in disease-associated signaling networks 41638470Feb41795784Mar.

Collectively, these publications suggest that EGFR/SRC-mediated EMT is being investigated as a key signaling module in cancer progression, metastasis, and therapy resistance, with studies using network pharmacology, transcriptomics, molecular docking, and in vivo or cell-based assays to connect EGFR/SRC signaling to migratory and invasive phenotypes 42049326Apr41966746Apr41895184Mar41844053Mar. The reported interventions included imipramine, scutellarein, herbal formulations, and epigenetic combination therapy, with several studies pointing to suppression of EGFR- or SRC-linked pathways as part of their anti-tumor effects 42049326Apr41966746Apr41831741Mar42313934Jun.

What Changes, What Holds

1. EGFR/SRC-linked EMT is now being used as a drug-response readout across diverse tumor models
REINFORCES Imipramine and scutellarein do not revise the core account of EGFR/SRC as an EMT-driving axis; they extend it by showing that anti-progression effects can be interpreted through suppression of this same signaling program in oral cancer and glioma 42049326Apr41966746Apr. The added value is translational rather than conceptual: EGFR/SRC-mediated EMT remains a plausible convergence point for anti-metastatic intervention, but these studies do not yet establish a new mechanism beyond the baseline.

2. EGFR/SRC-associated signaling remains a central adaptive and matrix-remodeling node, but the new work broadens its context
REINFORCES Restoration of bile acid efflux in hepatocellular carcinoma and epigenetic reprogramming in prostate cancer both fit the established view that EGFR-linked signaling and EMT cooperate with resistance, invasion, and extracellular-matrix remodeling 41903671Mar42313934Jun. What changes is emphasis: the recent studies place this axis alongside drug-resistance adaptation and collagen-rich stromal mechanics, sharpening how EMT is sustained, not replacing the baseline mechanism. The non-cancer network findings in stroke and kidney disease are context-setting rather than a challenge to the cancer-focused account 41638470Feb41795784Mar.

3. Network-based and multi-omics studies strengthen the case that EGFR/SRC is a recurring hub, but they do not settle causality
REINFORCES The recent literature makes EGFR/SRC look even more consistently central across computational and experimental pipelines, which supports the baseline claim that these proteins sit at a high-degree convergence point in cancer signaling 42049326Apr41966746Apr41895184Mar41844053Mar. What remains unsettled is whether hub status alone explains EMT behavior or merely tracks it; the new work is suggestive, not definitive, and the therapeutic implications still depend on direct mechanistic validation in each disease setting.

Overview update candidates: EGFR/SRC-mediated EMT is being used as a drug-response and resistance readout in specific Cancers; its link to extracellular-matrix remodeling and mechanotransduction is being sharpened; network and multi-omics studies continue to support EGFR/SRC as a recurring hub; though causality remains unsettled.